Pharmaceutical - Biocon

Filter

Current filters:

Biocon

Popular Filters

India loses its attraction for pharma clinical trials, as domestic regulations tighten

India loses its attraction for pharma clinical trials, as domestic regulations tighten

27-01-2014

Considered a global clinical trial hub three years ago, India has suffered a series of setbacks, with…

Asia-PacificBioconIndiaPharmaceuticalPiramal HealthcareRegulationResearch

Advaxis out-licenses ADXS-HPV to Biocon for emerging markets

Advaxis out-licenses ADXS-HPV to Biocon for emerging markets

23-01-2014

Indian biotech firm Biocon has entered into an exclusive licensing agreement for US cancer drug developer…

AdvaxisADXS-HPVAsia-PacificBioconIndiaLicensingOncologyPharmaceuticalWomen's Health

Bristol-Myers Squibb signs option for Biocon's oral insulin drug candidate

19-11-2012

Bangalore, India-based biotechnology firm Biocon (BSE: 532523) has entered into an option agreement with…

BioconBiotechnologyBristol-Myers SquibbDiabetesIN-105LicensingPharmaceuticalResearch

Pfizer and Biocon cancel biosimilars deal

14-03-2012

Indian biotech firm Biocon (BSE: 532523) and global drugs behemoth Pfizer (NYSE: PFE) yesterday announced…

Asia-PacificBioconBiotechnologyDiabetesInsulinLicensingNovo NordiskPfizerPharmaceutical

Back to top